<DOC>
	<DOC>NCT01175226</DOC>
	<brief_summary>This study aims to evaluate the safety, tolerability and effectiveness of BTA798 on - shortening the length and reducing the symptoms of human rhinovirus infection (also known as the common cold), - controlling asthma symptoms, and - lowering the risk of asthma symptoms worsening in subjects with asthma.</brief_summary>
	<brief_title>A Phase 2 Study of BTA798 in Asthmatic Adults With Symptomatic Human Rhinovirus Infection</brief_title>
	<detailed_description>Subjects with a previous diagnosis of asthma will be pre screened within 90 days prior to enrolment. If a subject develops symptoms of human rhinovirus (HRV) infection they will visit the site for assessment. Symptomatic subjects meeting all eligibility criteria will be invited to enroll.</detailed_description>
	<criteria>Male and female subjects aged 1870 years Diagnosis of asthma consistent with Global Initiative for Asthma (GINA) steps 1 to 3 Presumptive human rhinovirus infection Current severe asthma exacerbation Severe asthma, GINA steps 4 or higher Uncontrolled or clinically significant medical condition, disease or event which could impact subject safety and/or study evaluations and/or compliance to the protocol Current smoker, exsmoker of &lt;1 year, or history of smoking &gt;/=10 pack years.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Human rhinovirus</keyword>
	<keyword>Aviragen Therapeutics, Inc.</keyword>
	<keyword>Aviragen Therapeutics</keyword>
	<keyword>Aviragen</keyword>
</DOC>